相关实验视频
Updated: Jun 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PD-1和PD-L1基因多态与癌症风险的关联:基于50项研究的元分析
Maoquan Yang1, Yan Liu2, Shuangshuang Zheng3
1School of Clinical Medicine, Shandong Second Medical University, Weifang 261042, Shandong, China.
这项元分析发现,编程死亡-1 (PD-1) 和其连接物-1 (PD-L1) 的特定遗传变异与各种癌症风险有显著联系. 这些发现突显了PD-1/PD-L1多形态在癌症倾向中的作用.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 编程死亡-1 (PD-1) 和它的配体-1 (PD-L1) 是关键的免疫检查点蛋白调节抗瘤反应.
- 关于PD-1/PD-L1多态性和癌症风险的现有研究表明结果不一致.
研究的目的:
- 进行元分析,调查PD-1/PD-L1单核酸多态 (SNP) 与癌症倾向之间的关联.
- 为了澄清有关PD-1/PD-L1SNP和癌症风险的不一致证据.
主要方法:
- 进行了全面的元分析.
- 综合了多项评估PD-1/PD-L1SNP及其与各种癌症类型的相关性研究的数据.
主要成果:
- PD-1.3和PD-L1 rs17718883 SNPs与整体癌症风险有显著的相关性.
- 特定的SNP如PD-1.5,PD-1.9,PD-1.3,PD-1.1,rs4147815,PD-1.6,PD-L1rs2890658,rs17718883,rs10815225和rs2297136显示与肺癌,乳腺癌,卵巢癌,胃癌和肝癌等多种癌症的风险存在显著关联.
- 一些SNP表明了种族特异性影响,rs7421861和rs10815225降低了亚洲人的癌症易感性,rs7421861降低了白人风险.
结论:
- PD-1和PD-L1SNP与癌症风险有显著的相关性.
- 这些遗传变异在不同人群的癌症倾向中起着至关重要的作用.
- 这些发现为与免疫检查点相关的癌症易感性遗传基础提供了宝贵的见解.
更多相关视频
10:11Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
相关概念视频
Single Nucleotide Polymorphisms-SNPs
Cancer Prevention
Some...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-LTR Retrotransposons